	e:May. 26th, 2022		
	r Name:Ritsu Ibusuki	_	
			ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
			n advanced nonsquamous non-small cell lung cancer
Mai	nuscript number (if known):		
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
ıcıa	tionship, activity, interest, it	. is preferable that you do	30.
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to t	he epidemiology of hyperter	nsion, you should declare	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
med	lication, even if that medica	tion is not mentioned in th	ne manuscript.
In it	om #1 holow ronart all cum	nort for the work reported	in this manuscript without time limit. For all other items
	time frame for disclosure is	-	in this manuscript without time limit. For all other items,
uie	tille frame for disclosure is	the past 56 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	Inlanning of the work
1	All support for the present	_X_None	planning of the work
_	manuscript (e.g., funding,	ANone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	_X_None	
_	,		

Consulting fees

\_X\_None

5	Payment or honoraria for lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	X_None	
	pending		
	5	V M	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	XNone	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
N	lone.		

Date	e:May. 26th, 2022		
You	r Name:Yasuto Yoneshir	ma	
Mar	nuscript Title: Association	of thyroid transcription fa	ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
inhil	bitors plus pemetrexed and	platinum chemotherapy in	advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
relate part to trelate man. The to the med. In it.	ted to the content of your mies whose interests may be cansparency and does not not it in the following questions apply to cuscript only.  author's relationships/active epidemiology of hyperter lication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationships wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initial	nlanning of the work
1	All support for the present	_X_None	planning of the work
1	All support for the present manuscript (e.g., funding,	A_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	X_None	
	pending		
	5	V M	
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	XNone	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the foll	owing box:
N	lone.		

	e:May. 26th, 2022		
	r Name:Mikiko Hashisak		
Mar	nuscript Title: Association	of thyroid transcription fa	ctor—1 (TTF-1) expression with efficacy of PD-1/PD-L1
inhi	bitors plus pemetrexed and	platinum chemotherapy i	n advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
relar part to to to relar The man	ted to the content of your naties whose interests may be ransparency and does not not interest, in following questions apply the content only.  author's relationships/active epidemiology of hypertedication, even if that medications in the content on the content	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship vities/interests should be on nsion, you should declare ation is not mentioned in the	es/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		the past so months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		ualatianahin au indicata	!4!44! \
		relationship or indicate	institution)
		none (add rows as	institution)
		none (add rows as needed)	
		none (add rows as	
1	All support for the present	none (add rows as needed)	
1	manuscript (e.g., funding,	none (add rows as needed) Time frame: Since the initia	
1	manuscript (e.g., funding, provision of study materials,	none (add rows as needed) Time frame: Since the initia	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	none (add rows as needed) Time frame: Since the initia	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initia	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	none (add rows as needed) Time frame: Since the initia	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initia	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed)  Time frame: Since the initiaX_None	I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	none (add rows as needed)  Time frame: Since the initiaX_None  Time frame: pass	I planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	none (add rows as needed)  Time frame: Since the initiaX_None	I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	none (add rows as needed)  Time frame: Since the initiaX_None  Time frame: pass	I planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	none (add rows as needed)  Time frame: Since the initiaX_None  Time frame: pastX_None	I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	none (add rows as needed)  Time frame: Since the initiaX_None  Time frame: pass	I planning of the work

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

Date	e:May. 26th, 2022		
	r Name:Norikazu Matsu		
Man	uscript Title: Association	of thyroid transcription fa	ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
		-	n advanced nonsquamous non-small cell lung cancer
Man	uscript number (if known):		
relate part to trelate The man The to the med	ted to the content of your miles whose interests may be cansparency and does not notionship/activity/interest, it following questions apply to uscript only.  author's relationships/activity e epidemiology of hyperterication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	time name for disclosure is	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	
_	manuscript (e.g., funding,	ANone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V None	
3	Royalties or licenses	X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

	e:May. 26th, 2022		
	r Name:Taishi Harada		
			actor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
	-		n advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
relar to trelar The man	ted to the content of your name ites whose interests may be ransparency and does not not interest, it following questions apply the content only.	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do o the author's relationship vities/interests should be on nsion, you should declare	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
In it	•	•	d in this manuscript without time limit. For all other items,
In it	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
In it	•	•	d in this manuscript without time limit. For all other items,  Specifications/Comments
In it	•	the past 36 months.	
In it	•	the past 36 months.  Name all entities with	Specifications/Comments
In it	•	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your
In it	•	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	•	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	•	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	time frame for disclosure is	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialX_None	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialX_None	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia _X_None  Time frame: pas _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

Date	e:May. 26th, 2022		
You	r Name:Yuko Tsuchiya-K	awano	
Mar	nuscript Title: Association	of thyroid transcription fa	ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
inhi	bitors plus pemetrexed and	platinum chemotherapy in	advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
In the relation to the relatio	ne interest of transparency, ted to the content of your name interests may be ransparency and does not not it in the content of your name it in the content of your name it is a second of the content of	we ask you to disclose all reparts of the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the port for the work reported	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate none (add rows as needed)	institution)
		Time frame: Since the initial	nlanning of the work
1	All support for the present	_X_None	planning of the Work
1	manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V Nove	
3	Royalties or licenses	X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

Var-	e:May. 26th, 2022		
	r Name:Junji Kishimoto_		
			actor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
			n advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
rela part to to rela  The mar  The to	ted to the content of your modes whose interests may be ransparency and does not not itionship/activity/interest, it following questions apply to auscript only.  author's relationships/activity of hyperterestication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship vities/interests should be go nsion, you should declare ation is not mentioned in the	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate	
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	All support for the present	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding,	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	(e.g., if payments were made to you or to your institution)  I planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialX_None	(e.g., if payments were made to you or to your institution)  I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone  Time frame: pas	(e.g., if payments were made to you or to your institution)  I planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia _X_None  Time frame: past_X_None	(e.g., if payments were made to you or to your institution)  I planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initiaXNone  Time frame: pas	(e.g., if payments were made to you or to your institution)  I planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia _X_None  Time frame: past_X_None	(e.g., if payments were made to you or to your institution)  I planning of the work

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

	e:May. 26th, 2022		
	r Name:Keiichi Ota	of thuroid transcription fa	ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
	<del></del>	-	advanced nonsquamous non-small cell lung cancer
	nuscript number (if known):		radvanced nonsquamous non-small centung cancel
iviai	idseripe namber (ii knowil).		
In th	ne interest of transparency,	we ask you to disclose all	relationships/activities/interests listed below that are
			ns any relation with for-profit or not-for-profit third
part	ies whose interests may be	affected by the content of	the manuscript. Disclosure represents a commitment
to tr	ransparency and does not no	ecessarily indicate a bias.	If you are in doubt about whether to list a
rela	tionship/activity/interest, it	is preferable that you do	so.
	= :	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
man	uscript only.		
Tho	author's relationships/activ	uitios/intorosts should be d	lefined broadly. For example, if your manuscript pertains
			all relationships with manufacturers of antihypertensive
	lication, even if that medica	· · ·	-
····co	meation, even il that illearea	tion is not inclinioned in th	ic manascript.
In it	em #1 below, report all sup	port for the work reported	l in this manuscript without time limit. For all other items,
	time frame for disclosure is	<u>-</u>	· ,
		•	
		T	
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)
		none (add rows as	institution)
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

\_X\_\_None

\_X\_None

3

Royalties or licenses

Consulting fees

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

Date	e:May. 26th, 2022		
	r Name:Yoshimasa Shira		
Mar	nuscript Title: Association	of thyroid transcription fac	ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
inhil	bitors plus pemetrexed and	platinum chemotherapy in	advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
relate part to trelate The man	ted to the content of your mies whose interests may be cansparency and does not not it in the following questions apply to cuscript only.  author's relationships/active epidemiology of hyperter lication, even if that medical	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationships wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	_X_None	planning of the work
1	manuscript (e.g., funding,	ANone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

	e:May. 26th, 2022		
	r Name:Eiji Iwama		
			ctor–1 (TTF-1) expression with efficacy of PD-1/PD-L1
	-		n advanced nonsquamous non-small cell lung cancer
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your miles whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the current
to t		nsion, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	·	l in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	_X_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

Royalties or licenses

Consulting fees

\_X\_None

\_X\_None

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Chugai Pharma AstraZeneca Lilly	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	_X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X_None	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None	
13	Other financial or non- financial interests	_X_None	
	he author reports personal		owing box: naceutical, AstraZeneca and Lilly.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

	e:May. 26th, 2022		
	r Name:Kentaro Tanaka	<del></del>	
			ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
			advanced nonsquamous non-small cell lung cancer
Mai	nuscript number (if known):		
rela part to t	ted to the content of your n ies whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to t		nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive me manuscript.
	em #1 below, report all sup time frame for disclosure is	•	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	·
		needed)	
		Time frame: Since the initia	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

\_X\_\_None

5	Payment or honoraria for lectures, presentations,	Chugai Pharma	
	speakers bureaus,	Lilly	
	manuscript writing or	MSD	
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
	Stock of Stock options		
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		
	ase summarize the above co		owing box: acceutical, Lilly and MSD.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:May. 26th, 2022		
You	r Name:Yoshinao Oda		
Man	uscript Title: Association	of thyroid transcription fa	ctor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
inhil	pitors plus pemetrexed and	platinum chemotherapy ir	n advanced nonsquamous non-small cell lung cancer
Man	uscript number (if known):		
relate part to trelate The man The to the med	ted to the content of your miles whose interests may be cansparency and does not notionship/activity/interest, it following questions apply to uscript only.  author's relationships/activity e epidemiology of hyperterication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2	Constant of the constant of th	Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
3	in item #1 above).	V None	
3	Royalties or licenses	X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for lectures, presentations,	X_None	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Cumpart for attending	_X_None	
/	Support for attending meetings and/or travel	_x_none	
_			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	_X_None	
9	Safety Monitoring Board or	A_None	
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X_None	
		** **	
12	Receipt of equipment,	XNone	
12	materials, drugs, medical	_X_None	
12	materials, drugs, medical writing, gifts or other	_X_None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	
	materials, drugs, medical writing, gifts or other services		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	_X_None	lowing box:

Date:May. 26th, 2022
Your Name:Isamu Okamoto
Manuscript Title: Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1
inhibitors plus pemetrexed and platinum chemotherapy in advanced nonsquamous non–small cell lung cancer
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_X_None	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chugai Pharma AstraZeneca MSD Oncology Lilly Boehringer Ingelheim Ono Pharmaceutical Taiho Pharmaceutical Bristol-Myers Squibb Astellas Pharma Novartis AbbVie	

3	Royalties or licenses	XNone	
4	Consulting fees	X_None	
5	Payment or honoraria for	Chugai Pharma	
	lectures, presentations,	AstraZeneca	
	speakers bureaus,	MSD Oncology	
	manuscript writing or educational events	Lilly	
		Boehringer Ingelheim	
		Ono Pharmaceutical	
		Taiho Pharmaceutical	
		Bristol-Myers Squibb	
		Pfizer	
6	Payment for expert	_X_None	
	testimony		
7	Support for attending	_X_None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
4.0	Advisory Board	Y Y	
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

#### Please summarize the above conflict of interest in the following box:

The author reports grants and personal fees from Chugai Pharmaceutical, Astrazeneca, MSD, Lilly, Boheringer Ingelheim, Ono pharmaceutical, Taiho Pharmaceutical and Bristol-Myers Squibb; grants from Astellas Pharma, Novartis, and AbbVie; and personal fees from Pfizer outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.